HOME > TOP STORIES
TOP STORIES
-
TRENDS As Biosimilars Show Mixed Performances, Lantus Follow-On Is on a Roll
July 13, 2018
-
BUSINESS Otsuka Ventures into Antibody Space with Visterra Buyout
July 12, 2018
-
REGULATORY MHLW Selects 9 Priority Prefectures for Generic Promotion Project, but Leaves Tokyo Out
July 12, 2018
-
REGULATORY MHLW Official Expounds on “Authorized Biosimilar” Pricing, 50% Generic Rule Applies for “Biosame” Products
July 11, 2018
-
REGULATORY Tokyo Govt to Launch Support Program for Drug Discovery Startups to Solve Obstacles to Fundraising, IP Strategy
July 10, 2018
-
BUSINESS New Takeda Global Headquarters Designed for LGBT Inclusion
July 9, 2018
-
BUSINESS No Drug Breaks 100 Billion Yen Mark in FY2017 Japan Sales Ranking: Jiho Tally
July 6, 2018
-
BUSINESS Pfizer Wringing Hands over PMP Eligibility for Lorlatinib; It Might Earn 1st Conditional OK, but It’s “4th” ALK Inhibitor
July 5, 2018
-
REGULATORY Several Brand-Name Drug Makers Intend to Withdraw “G1” LLPs
July 4, 2018
-
TRENDS Japan Drug Makers Downsizing Parent Companies; Takeda Sheds Over 1,000 People in Divestitures, R&D Rejig
July 3, 2018
-
REGULATORY MHLW Approves Entyvio, Imfinzi, Lynparza Breast Cancer Use, and More
July 3, 2018
-
BUSINESS Takeda Celebrates Grand Opening for New Global Headquarters
July 3, 2018
-
BUSINESS With Focus on CGRP, Development of New Generation of Preventive Treatments for Migraines Heating Up
July 2, 2018
-
BUSINESS Grilled by Shareholders, Takeda CEO Seeks Understanding for Shire Deal
June 29, 2018
-
BUSINESS Takeda Shareholders Strike Down Dissident Group’s Proposal
June 28, 2018
-
BUSINESS Keytruda’s MSI-H Cancer Indication to Be Reviewed Under Conditional Early Approval System
June 28, 2018
-
BUSINESS Chugai Chairman Prods Drug Makers to Innovate, Chides Calls for Relaxed Pricing
June 27, 2018
-
ACADEMIA Licensee Selection Draws Near for AMED-Backed Cancer Mouth Sores Treatment
June 26, 2018
-
BUSINESS Xofluza Likely to Jolt Japan Flu Market This Winter
June 25, 2018
-
BUSINESS Maviret Sweeping Japan Hep C Market, 80% Share Snatched in Just 4 Months?
June 22, 2018
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
